Research programme: interleukin-16 based therapies - Sedecim Therapeutics

Drug Profile

Research programme: interleukin-16 based therapies - Sedecim Therapeutics

Latest Information Update: 26 Apr 2007

Price : $50

At a glance

  • Originator Sedecim Therapeutics
  • Class
  • Mechanism of Action Interleukin 16 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; HIV infections; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 15 Nov 2001 Preclinical development for Rheumatoid arthritis in USA (Unknown route)
  • 15 Nov 2001 Preclinical development for Inflammatory bowel disease in USA (Unknown route)
  • 15 Nov 2001 Preclinical development for HIV infections treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top